Hologic, Cytyc shareholders say yes to merger deal

By Lisa Kerner

Charlotte, N.C., Oct. 18 - Hologic, Inc. said its stockholders voted "overwhelmingly" to approve the company's merger with Cytyc Corp. at a special meeting on Thursday. The transaction is slated to close next week.

More than 90% of the shares represented at the meeting and more than 70% of the outstanding shares of Hologic were voted in favor of the transaction, a company news release stated.

Cytyc also reported that its shareholders approved the merger agreement at its special meeting on Thursday. More than 76% of the company's outstanding shares were voted in favor of the transaction.

Under the May 20 merger agreement, Cytyc stockholders will receive 0.52 of a share of Hologic common stock and $16.50 in cash for each share of Cytyc common stock they own for a total consideration of approximately $6.2 billion.

"We are excited about bringing together two well-respected industry leaders in the women's healthcare and diagnostics marketplace, and we are eager to begin working with our colleagues at Cytyc to realize the benefits this combination will bring to stockholders, employees, physicians and their patients," Hologic chairman and chief executive officer Jack Cumming said in the company's release.

Hologic is a diagnostic and medical imaging company based in Bedford, Mass.

Cytyc is a medical device company based in Marlborough, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.